Literature DB >> 15331843

Update on the clinical development of candidate malaria vaccines.

W Ripley Ballou1, Myriam Arevalo-Herrera, Daniel Carucci, Thomas L Richie, Giampietro Corradin, Carter Diggs, Pierre Druilhe, Birgitte K Giersing, Allan Saul, D Gray Heppner, Kent E Kester, David E Lanar, Jeff Lyon, Adrian V S Hill, Weiqing Pan, Joe D Cohen.   

Abstract

The recent availability of significantly increased levels of funding for unmet medical needs in the developing world, made available by newly created public-private-partnerships, has proven to be a powerful driver for stimulating clinical development of candidate vaccines for malaria. This new way forward promises to greatly increase the likelihood of bringing a safe and effective vaccine to licensure. The investigators bring together important published and unpublished information that illuminates the status of malaria vaccine development. They focus their comments on those candidate vaccines that are currently in or expected to enter clinical trials in the next 12 months. Copyright 2004 The American Society of Tropical Medicine and Hygiene

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331843

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  36 in total

Review 1.  Vaccines for preventing malaria (SPf66).

Authors:  P Graves; H Gelband
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys.

Authors:  Sheetij Dutta; Deep C Kaushal; Lisa A Ware; Sunil K Puri; Nuzhat A Kaushal; Atul Narula; D S Upadhyaya; David E Lanar
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  Building better T-cell-inducing malaria vaccines.

Authors:  Stephen M Todryk; Michael Walther
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

Review 4.  Towards an effective malaria vaccine.

Authors:  Pedro Aide; Quique Bassat; Pedro L Alonso
Journal:  Arch Dis Child       Date:  2007-06       Impact factor: 3.791

5.  Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus.

Authors:  Ming Yang; Matthew Dent; Huafang Lai; Haiyan Sun; Qiang Chen
Journal:  Vaccine       Date:  2017-06-29       Impact factor: 3.641

6.  Characterisation of PfRON6, a Plasmodium falciparum rhoptry neck protein with a novel cysteine-rich domain.

Authors:  Nicholas I Proellocks; Lev M Kats; David A Sheffield; Eric Hanssen; Casilda G Black; Karena L Waller; Ross L Coppel
Journal:  Int J Parasitol       Date:  2008-11-27       Impact factor: 3.981

7.  Acquisition of antibodies to merozoite surface protein 3 among residents of Korogwe, north eastern Tanzania.

Authors:  Method D Segeja; Bruno P Mmbando; Misago D Seth; John P Lusingu; Martha M Lemnge
Journal:  BMC Infect Dis       Date:  2010-03-08       Impact factor: 3.090

8.  Identification and characterization of merozoite surface protein 1 epitope.

Authors:  Satarudra Prakash Singh; Bhartendu Nath Mishra
Journal:  Bioinformation       Date:  2009-08-17

9.  Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.

Authors:  John N Waitumbi; Samuel B Anyona; Carol W Hunja; Carolyne M Kifude; Mark E Polhemus; Douglas S Walsh; Chris F Ockenhouse; D Gray Heppner; Amanda Leach; Marc Lievens; W Ripley Ballou; Joe D Cohen; Colin J Sutherland
Journal:  PLoS One       Date:  2009-11-17       Impact factor: 3.240

10.  Characterization of immunoglobulin G antibodies to Plasmodium falciparum sporozoite surface antigen MB2 in malaria exposed individuals.

Authors:  Thanh V Nguyen; John B Sacci; Patricia de la Vega; Chandy C John; Anthony A James; Angray S Kang
Journal:  Malar J       Date:  2009-10-23       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.